GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Loans Receivable

SK Bioscience Co (XKRX:302440) Loans Receivable : ₩0 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SK Bioscience Co Loans Receivable?

SK Bioscience Co's Loans Receivable for the quarter that ended in Dec. 2023 was ₩0 Mil.


SK Bioscience Co Loans Receivable Historical Data

The historical data trend for SK Bioscience Co's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co Loans Receivable Chart

SK Bioscience Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial - - - - -

SK Bioscience Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

SK Bioscience Co Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


SK Bioscience Co Loans Receivable Related Terms

Thank you for viewing the detailed overview of SK Bioscience Co's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


SK Bioscience Co (XKRX:302440) Business Description

Traded in Other Exchanges
N/A
Address
310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494
SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co (XKRX:302440) Headlines

No Headlines